Direkt zum Inhalt
Merck

H4166

Sigma-Aldrich

Hydroxyflutamide

≥98% (HPLC)

Synonym(e):

2-Hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-propanamide, 2-Hydroxyflutamide, Hydroxyniphtholide, Sch 16423, a,a,a-Trifluoro-2-methyl-4′-nitro-m-lactotoluidide

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C11H11F3N2O4
CAS-Nummer:
Molekulargewicht:
292.21
MDL-Nummer:
UNSPSC-Code:
51111800
PubChem Substanz-ID:
NACRES:
NA.77

Qualitätsniveau

Assay

≥98% (HPLC)

Form

powder

Lagerbedingungen

desiccated

Farbe

white to tan

Löslichkeit

DMSO: >10 mg/mL

Ersteller

Schering Plough

Lagertemp.

room temp

SMILES String

CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O

InChI

1S/C11H11F3N2O4/c1-10(2,18)9(17)15-6-3-4-8(16(19)20)7(5-6)11(12,13)14/h3-5,18H,1-2H3,(H,15,17)

InChIKey

YPQLFJODEKMJEF-UHFFFAOYSA-N

Anwendung

Hydroxyflutamide has been used:
  • as an androgen receptor antagonist to study its effects on cardiomyocyte hypertrophy induced by dihydrtestosterone (DHT) in primary neonatal rat ventricular cardiomyocyte and rat cardio myoblast (H9c2) cells.
  • as an androgen receptor antagonist for the treatment of MDA-kb2 cells to check its effect on luciferase expression.
  • as an antagonist control in transcriptional activation assay.

Biochem./physiol. Wirkung

Hydroxflutamide is an AR (androgen receptor) antagonist.
Hydroxflutamide is an AR antagonist. Androgen receptors (ARs) are nuclear hormone receptors/transcription factors. Hydroxyflutamide is an androgen antagonist with publications going back to 1981. It is one of a few gold standard AR antagonists; activities of new antagonists are measured against hydroxyflutamide.
Hydroxyflutamide plays a role in preventing the binding of 5α-dihydrotestosterone (DHT) and testosterone to the androgen receptors.

Leistungsmerkmale und Vorteile

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Piktogramme

Exclamation mark

Signalwort

Warning

Gefahreneinstufungen

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Zielorgane

Respiratory system

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Anticancer Drugs That Modulate Hormone Action
Medicinal Chemistry of Anticancer Drugs, 81-131 (2015)
De Facto Water Reuse: Bioassay suite approach delivers depth and breadth in endocrine active compound detection
Kakaley E K, et al.
The Science of the Total Environment, 699, 134297-134297 (2020)
Seva E Kostrubsky et al.
Chemical research in toxicology, 20(10), 1503-1512 (2007-09-29)
Treatment with flutamide has been associated with clinical hepatotoxicty. The toxicity, metabolism,and transport of flutamide were investigated using cultured human hepatocytes. Flutamide and its major metabolite, 2-hydroxyflutamide, caused an inhibition of taurocholate efflux in human hepatocytes with an IC50=75 microM
Jennifer C Brennan et al.
Toxicology in vitro : an international journal published in association with BIBRA, 47, 18-25 (2017-11-07)
There is a need to adapt cell bioassays to 384-well and 1536-well formats instead of the traditional 96-well format as high-throughput screening (HTS) demands increase. However, the sensitivity and performance of the bioassay must be re-verified in these higher micro-well
Thomas Andrieu et al.
Biochemical pharmacology, 82(11), 1651-1662 (2011-09-13)
Prostate cancer (PCa) progression is enhanced by androgen and treatment with antiandrogens represents an alternative to castration. While patients initially respond favorably to androgen ablation therapy, most experience a relapse of the disease within 1-2 years by expressing androgen receptor

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.